Implementing the treatment of heart failure with SGLT-2 inhibitors and sacubitril-valsartan: does money matter?

Eur J Prev Cardiol. 2021 Dec 29;28(15):1670-1672. doi: 10.1093/eurjpc/zwaa153.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Aminobutyrates / adverse effects
  • Biphenyl Compounds
  • Drug Combinations
  • Heart Failure* / diagnosis
  • Heart Failure* / drug therapy
  • Humans
  • Sodium-Glucose Transporter 2 Inhibitors* / adverse effects
  • Valsartan

Substances

  • Aminobutyrates
  • Biphenyl Compounds
  • Drug Combinations
  • Sodium-Glucose Transporter 2 Inhibitors
  • sacubitril
  • Valsartan